10x Genomics (TXG) Receivables - Net (2018 - 2025)
Historic Receivables - Net for 10x Genomics (TXG) over the last 8 years, with Q4 2025 value amounting to $47.0 million.
- 10x Genomics' Receivables - Net fell 4649.22% to $47.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $47.0 million, marking a year-over-year decrease of 4649.22%. This contributed to the annual value of $47.0 million for FY2025, which is 4649.22% down from last year.
- Latest data reveals that 10x Genomics reported Receivables - Net of $47.0 million as of Q4 2025, which was down 4649.22% from $43.8 million recorded in Q3 2025.
- 10x Genomics' Receivables - Net's 5-year high stood at $114.8 million during Q4 2023, with a 5-year trough of $43.8 million in Q3 2025.
- Its 5-year average for Receivables - Net is $77.6 million, with a median of $81.0 million in 2021.
- Per our database at Business Quant, 10x Genomics' Receivables - Net soared by 16260.67% in 2021 and then crashed by 4758.58% in 2025.
- Quarter analysis of 5 years shows 10x Genomics' Receivables - Net stood at $85.3 million in 2021, then rose by 22.24% to $104.2 million in 2022, then increased by 10.19% to $114.8 million in 2023, then dropped by 23.49% to $87.9 million in 2024, then crashed by 46.49% to $47.0 million in 2025.
- Its last three reported values are $47.0 million in Q4 2025, $43.8 million for Q3 2025, and $50.0 million during Q2 2025.